
Biodesix (BDSX) Stock Forecast & Price Target
Biodesix (BDSX) Analyst Ratings
Bulls say
Biodesix is positioned for continued success due to their strong financial performance, expanding market share, and innovative product pipeline. However, they face competition in the diagnostic testing industry and must continue to invest in research and development to stay ahead. Overall, the company shows promise in both financial growth and scientific advancements, making it a positive investment opportunity for the future.
Bears say
Biodesix is heavily reliant on its Nodify portfolio of blood-based lung screening tests for its current and future success, which holds a significant market opportunity of 10 million annual testing opportunities and $27 billion annual market. However, there are several risks to achieving the projected price target, including competition from upcoming competitors, potential low revenue growth, and inability to achieve sustainable profitability. Additionally, the company's reliance on timely and favorable reimbursement decisions may also impact its future revenue growth.
This aggregate rating is based on analysts' research of Biodesix and is not a guaranteed prediction by Public.com or investment advice.
Biodesix (BDSX) Analyst Forecast & Price Prediction
Start investing in Biodesix (BDSX)
Order type
Buy in
Order amount
Est. shares
0 shares